


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.10%
+0.98%
+15.07%
CELC
Celcuity
$100.00
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
Risk Analysis

Investors losing their confidence
CELC Price Performance
$74.59 (+34.07%)
$60.77 (+64.55%)
$13.75 (+627.27%)
$12.55 (+696.81%)
CELC has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

High volatilty

CELC overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow
![]()
CELC Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
CELC Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is CELC current stock price?
What are CELC stock strengths?
What is CELC Risk Level?
What is CELC market cap and volume?
What is CELC current Stock IQ?
Should I buy CELC stock right now?
Is CELC a Strong Buy right now?
What does a 'Strong Buy' rating mean for CELC?
What does a 'Strong Sell' rating mean for CELC?
What factors influence CELC's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.10%
+0.98%
+15.07%
CELC
Celcuity
Current Price
$100.00
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
Risk Analysis

Investors losing their confidence

CELC Price Performance
$74.59 (+34.07%)
$60.77 (+64.55%)
$13.75 (+627.27%)
$12.55 (+696.81%)
CELC Analysts Opinion
CELC Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow
![]()
CELC Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
CELC Street Sentiment is extremely bullish and have positive views on the near-term outlook
CELC has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

High volatilty

Average key support and resistance price levels
CELC Stock IQ
CELC Latest Analysis
Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In. Key PointsSan Diego-based Tang Capital Management bought nearly 1.2 million CELC shares.
Tue Dec 2, 2025
Jefferies Maintains Celcuity (CELC) Buy Recommendation. Fintel reports that on December 2 2025 Jefferies maintained coverage of Celcuity (NasdaqCM:CELC) with a Buy recommendation. Analyst Price Forecast Suggests 0.83% Downside
Tue Dec 2, 2025
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results. Key PointsNew York City-based Apis Capital Advisors added 776000 shares in CELC during the third quarter establishing a position valued at $38.3 million.
Fri Nov 28, 2025
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium. MINNEAPOLIS Nov. 26 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) a clinical-stage biotechnology company pursuing development of targeted therapies for oncology today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS
Wed Nov 26, 2025
Notable Tuesday Option Activity: CELC FHN VSTS. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Celcuity Inc (Symbol: CELC) where a total volume of 5472 contracts has been traded thus far today a contract volume which is representative of approximately 5
Tue Nov 18, 2025
Celcuity Analyst No Longer ish Despite Breast Cancer Therapy Application. The Food and Drug Administration agreed to accept the NDA application for the approval of ) The stock already prices in the prospects according to HC Wainwright.Analyst Swayampakula Ramakanth downgraded the rating from Buy to Neutral while raising the price target from $77 to $94.
Mon Nov 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CELC Stock trends
CELC Stock performance
CELC Stock analysis
CELC investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.